It’s worth noting that the good response of AML cell lines with KMT2A rearrangement to narazaciclib might be a result of the SIK-3 inhibition by narazaciclib, although this additional anti-AML effect of narazaciclib via targeting SIK-3 remains further investigation. The gene discussed is SIK3; the disease is acute myeloid leukemia.